C2Kit 、PD GFRα的表达与卵巢浆液性 癌顺铂耐药的临床研究
Expression of c2KIT – PDGFRαand Correlation with Chemotherapy Resistance in Ovarian Serous Carcinomas :A Cl inical Study
-
摘要: 目的 分析C2Kit 、PDGFRα在卵巢浆液性癌中的表达及其与铂类耐药的关系, 以期为顺铂耐药的卵巢癌治疗提供实验室依据。方法 采用免疫组化SP 法检测C2Kit 、PDGFRα在59 例卵巢浆液性癌中的表达,并分析两者的表达与卵巢浆液性癌顺铂耐药的关系。结果 C2Kit 、PDGFRα在59 例卵巢浆液性癌中的阳性表达率分别为57. 63 %和66. 10 %。C2Kit 蛋白阳性表达与卵巢浆液性癌化疗铂类耐药有关( P < 0. 05), 而PDGFRα蛋白阳性表达与卵巢浆液性癌化疗铂类耐药无关( P > 0. 05) 。C2Kit 、PDGFRα的表达与卵巢浆液性癌组织学分级和临床分期有关( P < 0. 01或P < 0. 05) 。结论 C2Kit 蛋白阳性表达与卵巢浆液性癌顺铂耐药有关,而PDGFRα表达与卵巢浆液性癌顺铂耐药无关。Abstract: Objective To investigate the expressions of C2Kit and PDGFRα and their correlation with chemotherapy resistance in ovarian serous carcinomas. Methods We undertook SP immunohistochemical technique to examine the expressions of C2Kit and PDGFRαin 59 cases with ovarian serous carcinomas, usng archival paraffinembedded specimens. Then we observed the correlation with chemotherapy resist2 ance. Results C2Kit and PDGFRα immunostainings were observed positively expressed in 57. 63 % and 66. 10 % of cases. C2Kit expression was statistically correlated with progression of disease af ter first2line chemotherapy ( P < 0. 05), but PDGFRα was not statistically significant ( P > 0. 05) . There were great difference between of C2Kit and PDGFRα expressions in samples of different differentiated and clinical stages of ovarian serous carcinomas ( P < 0. 01 or P < 0. 05) . Conclusion C2Kit is statistically correlated with chemotherapy resistance, while PDGFRαis not correlated.
下载:
